Marker Evaluation for Avastin Research in colorectal cancer

Phase 1

• Conditions: Metastatic colorectal cancer; MedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2011-004755-39-IE
• Lead Sponsor: Genentech, Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-04-10
• Last Update Posted: 9 May 2016

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 360

Inclusion Criteria

a. Disease-specific inclusion criteria
1. Histologically or cytologically confirmed CRC with at least one
measurable metastatic lesion by RECIST, v1.1. (Baseline tumor assessments must be done within 28 days prior to randomization)
2. Archival tumor tissue sample (i.e., representative tumor tissue specimen in paraffin block [preferred] or at least 22 unstained slides) must be requested and available prior to study entry. If no archival tumor tissue sample is available, a fresh biopsy tissue sample must be obtained but should be discussed first with the medical monitor. A copy of the local pathology report must be submitted along with the specimens
b. General inclusion criteria
3. Signed informed consent prior to initiation of any study-specific procedure or treatment
4. Age >= 18 years
5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
6. Able to comply with the protocol, including tissue and blood sampling
7. Adequate hematological function:
Absolute neutrophil count >= 1500 per mm3 AND
Platelet count >= 100,000 per mm3 AND
Hemoglobin >= 9 g/dL (may be transfused to maintain or exceed this level)
8. Adequate liver function:
Total bilirubin < 1.5 x upper limit of normal (ULN) AND
Aspartate aminotransferase and alanine aminotransferase < 2.5 x ULN in patients without liver metastases or < 5 x ULN in patients with liver metastases
9. Adequate renal function:
Calculated creatinine clearance according to the formula of Cockroft and Gault >= 50 mL/min AND
Urine for proteinuria should be < 2 +. Patients discovered to have >= 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate < 1 g of protein in 24 hours
10. International normalized ratio <= 1.5 and activated prothrombin time <= 1.5 x ULN for patients not receiving anti-coagulation therapy. The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or aPTT is within therapeutic limits (according to the medical standard of the enrolling institution) and the patient has been on a stable dose of anticoagulants for at least two weeks prior to the first study treatment
11. Patients with treated brain metastases are eligible for study participation. Patients may not receive ongoing treatment with steroids at screening. Anticonvulsants (at stable dose) are allowed. Treatment for brain metastases may be whole-brain radiotherapy, radiosurgery, neurosurgery, or a combination as deemed appropriate by the treating physician. Radiotherapy and stereotactic radiosurgery must be completed at least 28 days prior to randomization
12. Female patients should not be pregnant or breast-feeding. Female patients with childbearing potential should agree to use effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) during the study and for a period of at least 6 months following the last administration of study drugs. Female patients with an intact uterus (unless amenorrheic for the last 24 months) must have a negative serum pregnancy test within 7 days prior to randomization into the study
13. Male patients must agree to use effective contraception during the study and for a period of at least 6 months following the last administration of study drugs, even if they have been surgically sterilized.
Are the trial subjects under 18? no
Number of subjects for this age

Exclusion Criteria

a. Disease-specific exclusions
1. Any prior systemic treatment for metastatic CRC
2. Adjuvant chemotherapy for CRC completed < 12 months
3. Sensory peripheral neuropathy >= grade 2
4. Evidence of Gilbert’s Syndrome or of homozygosity for the UGT1A1*28 allele.
-Patients with Gilbert’s Syndrome may have a greater risk of irinotecan toxicity due to the abnormal glucuronidation of SN-38. Evidence of Gilbert’s Syndrome would include a prior finding of an isolated elevation of indirect bilirubin. UGT1A1 genotyping is not required on this study
5. Known positivity for human immunodeficiency virus (HIV)
b. General medical exclusions
6. Malignancies other than metastatic CRC within 5 years prior to
randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, and ductal carcinoma in situ treated surgically with curative intent
7. Radiotherapy to any site for any reason within 28 days prior to
randomization, except for palliative radiotherapy to bone lesions within 14 days prior to randomization
8. Clinically detectable (by physical exam) third-space fluid collections (e.g., ascites or pleural effusion) that cannot be controlled by drainage or other procedures prior to study entry
9. Treatment with any other investigational agent, or participation in another investigational drug trial within 28 days prior to randomization
c. Bevacizumab-specific exclusions
10. Evidence of any other disease, neurological or metabolic dysfunction, physical examination finding, or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of bevacizumab or puts the patient at high risk for treatment-related complications
11. Surgery (including open biopsy), significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during study treatment
12. Minor surgery, including insertion of an indwelling catheter, within 24 hours prior to the first bevacizumab infusion
13. Current or recent (within 10 days prior to first dose of bevacizumab) use of aspirin (> 325 mg/day). Prophylactic and therapeutic use of anticoagulants is allowed, e.g., warfarin (1 mg QD) for catheter prophylaxis, and prophylactic low molecular-weight heparin (i.e., enoxaparin [40 mg QD]). Current or recent (within 10 days prior to first dose of bevacizumab) use of full dose (i.e., therapeutic dose) of thrombolytic agents for therapeutic purposes
14. History or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleeding
15. Inadequately controlled hypertension (blood pressure: systolic > 150 mmHg and/or diastolic > 100 mmHg)
16. Clinically significant (i.e., active) cardiovascular disease (e.g.,
cerebrovascular accident or myocardial infarction within 6 months prior to randomization), unstable angina, congestive heart failure (New York Heart Association Class >= II,) or serious cardiac arrhythmia that is uncontrolled by medication or may interfere with administration of study treatment
17. Serious non-healing wound, active peptic ulcer, or untreated bone fracture
18. History of abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within 6 months of randomization
19. Known hypersensitivity to bevacizumab or any of its excipients or any other study drug

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified